Vectormune ND


Newcastle disease and Marek’s disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Vectormune ND. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Vectormune ND.

For practical information about using Vectormune ND, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 06/10/2020

Authorisation details

Product details
Vectormune ND
Agency product number
Active substance
cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain
International non-proprietary name (INN) or common name
Newcastle disease and Marek’s disease vaccine (live recombinant)
  • Chicken
  • Embryonated eggs
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
CEVA-Phylaxia Co. Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Szállás u. 5.
1107 Budapest

Product information

20/07/2020 Vectormune ND - EMEA/V/C/003829 - R/0013


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Live viral vaccines

Therapeutic indication

For active immunisation of 18 day-old embryonated chicken eggs or one-day-old chicks to reduce mortality and clinical signs caused by Newcastle disease virus and to reduce mortality, clinical signs and lesions caused by Marek’s disease virus with a phenotype "virulent".

Assessment history

How useful was this page?

Add your rating